Key Data on a First-Line Treatment Option for EGFRm mNSCLC

Host: Jennifer Caudle, DO <br> Guest: Tracey Evans, MD <br> <p>Join Dr. Tracey Evans as she discusses the efficacy data for TAGRISSO® (osimertinib) and the potential impact for metastatic EGFRm NSCLC patients.</p> <p>In 2018, first-line TAGRISSO became a standard of care for metastatic EGFRm NSCLC with an unprecedented <strong>18.9 months median PFS vs 10.2 months for erlotinib/gefitinib (HR=0.46 [95% CI: 0.37, 0.57]; <em>P</em>&lt;0.0001).¹</strong></p> <p>Now, TAGRISSO is the only EGFR TKI to deliver statistically significant Overall Survival beyond 3 years in a global, phase 3 randomized clinical trial in the first-line setting, (38.6 months vs 31.8 months for erlotinib/gefitinib (HR=0.799 [95.05% CI: 0.641, 0.997];<em> P</em>=0.0462)).²</p> <p>Visit <span style="text-decoration: underline;"><a href="https://www.tagrissohcp.com/"><strong><span style="color: blue; text-decoration: underline;">TagrissoHCP.com</span></strong></a></span> to learn what these data could mean for your patients.</p> <p><strong>FLAURA study design:</strong> Randomized, double-blind, active-controlled trial in 556 patients with metastatic EGFRm NSCLC who had not received prior systemic treatment for advanced disease. Patients were randomized 1:1 to either TAGRISSO (n=279; 80 mg orally, once daily) or EGFR-TKI comparator (n=277; gefitinib 250 mg or erlotinib 150 mg orally, once daily). All US patients in the comparator arm received erlotinib. Crossover was allowed for patients in the EGFR-TKI comparator arm at confirmed progression if positive for the EGFR T790M resistance mutation. Patients with CNS metastases not requiring ...